SAN DIEGO, Oct. 18, 2019 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) will present new open-label
extension data from the Phase 2 OASIS trial for its investigative
drug candidate etrasimod, a next-generation, once-daily, oral,
selective sphingosine 1-phosphate (S1P) receptor modulator, in
patients with moderately to severely active ulcerative colitis (UC)
at the 25th Annual United European Gastroenterology
(UEG) Week. Arena will also present data for olorinab, a
peripherally acting, highly selective, full agonist of the
cannabinoid receptor 2 (CB2), in development for the
treatment of visceral pain associated with gastrointestinal (GI)
diseases. UEG Week is taking place October
19-23, 2019, in Barcelona,
Spain.
In addition to the data presentations, Arena is sponsoring a
satellite breakfast symposium (details below) and exhibiting at
booth #78. Find out more about Arena's ongoing and planned clinical
trials in inflammatory bowel disease (IBD) and irritable bowel
syndrome (IBS).
Arena Sponsored Breakfast Symposium
Details:
Title: Will oral therapies change the IBD treatment
landscape?
Speakers: Professor Stefan Schreiber (Chair), Professor Ailsa Hart, & Professor Laurent Peyrin-Biroulet
Day/Time: Tuesday, October 22,
at 7:00am CEST
Location: Fira Gran Via, Hall 8 – Room A1
How: Learn more and register here
Etrasimod Presentation Details:
Title:
Long-term Efficacy and Safety of Etrasimod for Ulcerative
Colitis: Results from the Open- label Extension of the Oasis
Study
Session Date/Time: Monday, October 21, from 10:30 AM – 5:00 PM
CEST
Presentation Time: 12:30 – 1:30 PM
CEST
Presenting Author: Dr. Séverine Vermeire
Location: Poster Hall 7
Poster Identification: #P0403
Olorinab Presentation Details:
Title:
Preclinical and Clinical Efficacy of Olorinab, a Peripherally
Restricted, Highly Selective Full Agonist of the Cannabinoid
Receptor 2 for the Management of Visceral Pain in Inflammatory
Bowel Disease
Session Date/Time: Tuesday, October 22, from 10:30 AM – 12:00 PM
CEST
Presenting Author: Dr. Peter Higgins
Location: Hotspot
Abstract Identification: #OP212
About Etrasimod
Etrasimod (APD334) is a once-daily,
oral, selective sphingosine 1-phosphate (S1P) receptor modulator,
discovered by Arena, designed to provide systemic and local cell
modulation by targeting S1P receptor subtypes 1, 4 and 5. Etrasimod
has therapeutic potential in immune and inflammatory-mediated
diseases such as ulcerative colitis, Crohn's disease, and atopic
dermatitis. S1P receptors have been demonstrated to be involved in
the modulation of several biological responses, including
lymphocyte trafficking from lymph nodes to the peripheral blood. By
isolating subpopulations of lymphocytes in lymph nodes, fewer
immune cells are available in the circulating blood to effect
tissue damage.
About Olorinab
Olorinab (APD371) is an oral,
peripherally acting, highly selective, full agonist of cannabinoid
receptor 2 (CB2) in development for the treatment of
visceral pain associated with gastrointestinal (GI) diseases,
including Crohn's disease and irritable bowel syndrome (IBS).
Evidence that CB2 are expressed in multiple cell types
of the GI tract, and modulate intestinal inflammation and visceral
hypersensitivity, make CB2 an attractive target for the
treatment of abdominal pain in GI disorders.
Etrasimod and olorinab are investigational compounds that are
not approved for any use in any country.
About Arena Pharmaceuticals
Arena Pharmaceuticals is
driven to deliver novel, transformational medicines with optimized
pharmacology to patients globally. Arena's proprietary pipeline
includes multiple potentially first- or best-in-class assets with
broad clinical utility. Etrasimod (APD334), with potential
utility in a broad range of immune-mediated and inflammatory
conditions, is being evaluated in later-stage clinical programs in
ulcerative colitis (UC) and Crohn's disease (CD), as well as in
programs for other indications such as atopic dermatitis. Arena is
also evaluating olorinab (APD371) in a Phase 2 program for
gastrointestinal pain. Arena continues to assess other earlier
research and development stage drug candidates, including APD418
for decompensated heart failure.
Arena has additional license agreements and partnerships,
including with United Therapeutics (ralinepag in a Phase 3 program
for pulmonary arterial hypertension), Everest Medicines Limited
(etrasimod in Greater China and
select Asian countries), Boehringer Ingelheim International GmbH
(undisclosed target – preclinical), Outpost Medicine, LLC
(undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai
Inc. (BELVIQ® – marketed product).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. These forward-looking statements may be
identified by introductory words such as "will," "planned,"
"designed to," "potential," "in development for," "driven to,"
"potentially," "evaluating," or words of similar meaning, or by the
fact that they do not relate strictly to historical or current
facts. Such forward-looking statements include, without limitation,
statements about Arena's participation in UEG Week, including its
breakfast symposium, data presentations, and booth; the
opportunity, development and potential of etrasimod and olorinab;
Arena's drive; and the potential of Arena's assets, programs,
licenses, and partnerships. For such statements, Arena claims the
protection of the Private Securities Litigation Reform Act of 1995.
Actual events or results may differ materially from Arena's
expectations. Factors that could cause actual results to differ
materially from the forward-looking statements include those
disclosed in Arena's filings with the Securities and Exchange
Commission. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Corporate
Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial
Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, MD
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-presence-at-united-european-gastroenterology-week-bolsters-commitment-to-the-gastrointestinal-disease-community-300941014.html
SOURCE Arena Pharmaceuticals, Inc.